In experimental EAMG, microRNA miR-155-5p has been shown to inhibit Treg activation and immunosuppressive capacity by targeting BCL10, suggesting that BCL10 may represent a therapeutic target for the treatment of MG [116]. This evidence concerns the gene BCL10 and myasthenia gravis.